series-a
Stage
1
Investors
About
Cortexyme is a clinical-stage pharmaceutical company developing oral therapeutics that target bacterial proteases implicated in Alzheimer's disease and other neurodegenerative disorders to slow disease progression.
Explore Cortexyme's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.